Cystic Fibrosis (CF) is a genetic disorder that affects around 89,000 people worldwide. This condition arises from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which leads to impaired salt transport across cellular membranes. As a result, less water is transported through tissues, causing a thick, sticky mucus to accumulate in various parts of the body. This mucus build-up affects different organs, leading to a range of symptoms that significantly impact the quality of life and reduce life expectancy.

For decades, treatment for cystic fibrosis has relied primarily on managing symptoms. However, recent advances in our understanding of biochemistry and nutrition have brought nutraceuticals into the spotlight as potential therapeutic aids. Nutraceuticals are natural compounds that may provide health benefits beyond basic nutrition. They offer hope for alleviating some of the burdens caused by CF and can serve as an adjunct to conventional treatment approaches. This article delves into the nature of CF, its impact on organ function, and the potential of certain nutraceuticals to help manage the condition.

What is cystic fibrosis and how does it affect the body?

Cystic fibrosis results from mutations in the CFTR gene, which codes for a protein that regulates the movement of salt (chloride and bicarbonate) across cell membranes. This process is vital for maintaining hydration, as the movement of salt influences water transport. When the CFTR protein is either defective or absent, it leads to dehydration of the airway surfaces, resulting in thickened mucus that is difficult to clear.

This impaired mucus clearance affects several organs, most notably the lungs and the digestive system. Patients experience chronic respiratory infections and inflammation due to mucus trapping bacteria in the airways. They also suffer from digestive issues because mucus blocks the release of digestive enzymes from the pancreas, hindering nutrient absorption. Male infertility, CF-related diabetes, and liver disease are also common complications.

The F508del mutation is the most common genetic variant that causes CF, affecting around 90% of CF patients. This mutation results in a CFTR protein that is misfolded, preventing it from reaching the cell membrane. Without a functioning CFTR protein, the body's cells cannot effectively transport salt, leading to symptoms like chronic lung infections, malabsorption of nutrients, and elevated salt levels in sweat.

The lungs are particularly vulnerable in CF. Thick mucus in the airways leads to the formation of mucus plugs that obstruct airflow, causing small airway disease and, eventually, bronchiectasis. Patients experience frequent bacterial infections, primarily caused by Pseudomonas aeruginosa, a pathogen that thrives in the thick mucus. These infections can be resistant to antibiotics, contributing to progressive lung damage.

In addition to the respiratory tract, epithelial transport-which involves the movement of ions and other molecules across cell membranes-plays a crucial role in maintaining the function of organs like the lungs, intestines, and pancreas. Dysfunction in epithelial transport, due to defective CFTR, results in thick mucus secretions and digestive problems. For example, pancreatic enzyme deficiency prevents adequate digestion, leading to malnutrition in CF patients.

Conventional treatment and the rise of nutraceuticals

Securing an accurate diagnosis of cystic fibrosis is critical for effective treatment. With advancements in personalized therapies targeting the underlying defect in CFTR, early diagnosis allows for better management of the condition. Treatments include daily chest physiotherapy, inhaled medications, frequent use of antibiotics to treat infections, and nutritional supplements, including pancreatic enzymes. The advent of CFTR modulators has revolutionized CF treatment by improving the function of the CFTR protein. Drugs like ivacaftor and combination therapies such as tezacaftor + ivacaftor have been effective in improving lung function and quality of life for patients. Recently, a triple therapy of ivacaftor, tezacaftor, and elexacaftor has shown the ability to normalize chloride transport, significantly improving patient outcomes.

While CFTR modulators are a significant leap forward, there is increasing interest in nutraceuticals as complementary treatments. Nutraceuticals are substances derived from food sources that provide health benefits in addition to their nutritional value. In CF, they have shown promise in reducing inflammation, aiding mucus clearance, and supporting immune function. Below, we explore some of the nutraceuticals that hold potential for CF management.

Seaweeds: Nature's Answer to Antibiotic Resistance

Seaweeds have gained attention for their antimicrobial properties, especially in the face of rising antibiotic resistance. Compounds derived from seaweeds, such as phlorotannins and algal polysaccharides, have shown significant antibacterial effects, particularly against Pseudomonas aeruginosa biofilms. These biofilms are notorious for resisting antibiotic treatment, contributing to persistent infections in CF patients.

One promising compound from seaweed is OligoG, an alginate oligosaccharide derived from Laminaria hyperborea. It has been found to disrupt biofilm formation, reducing the dose of antibiotics needed to treat Pseudomonas infections. OligoG works by reducing the viscosity of biofilms and allowing antibiotics to penetrate more effectively. Current clinical trials are exploring the potential of inhaled OligoG for managing CF-related lung infections, showing that seaweeds could become valuable resources in combating drug-resistant infections.

CF patients often have imbalances in fatty acid metabolism, characterized by increased omega-6 and decreased omega-3 levels. Long-term supplementation with docosahexaenoic acid (DHA), a type of omega-3 fatty acid, has shown promising results. A dose of 50 mg/kg/day for 12 months has been shown to increase omega-3 levels and reduce inflammatory markers, suggesting potential benefits in improving overall health and reducing chronic inflammation in CF patients.

Curcumin: Anti-inflammatory potential

Curcumin, the active compound in turmeric, has garnered interest for its anti-inflammatory and antioxidant properties. In CF, curcumin can help mitigate some of the issues caused by defective CFTR channels, such as electrolyte imbalances and inflammation. It has been found to activate chloride channels, potentially aiding in reducing mucus viscosity and restoring electrolyte balance in the lungs and digestive system.

Curcumin also has properties that might slow the progression of CF by influencing cellular pathways involved in fibrosis (the formation of scar tissue). In addition, it can induce apoptosis (programmed cell death) in cells that contribute to excessive mucus production, thereby reducing the disease's impact on the respiratory and gastrointestinal tracts.

Glycine: Supporting respiratory function

Glycine, an amino acid, has shown potential as a nutraceutical for CF patients. Glycine can activate chloride channels in various tissues, improving chloride transport and reducing inflammation. It is also effective in counteracting oxidative stress in immune cells like macrophages, which play a crucial role in managing lung infections and inflammation.

Clinical trials using glycine supplementation at a dose of 0.5 g/kg/day for eight weeks showed significant improvements in lung function, measured by forced expiratory volume (FEV), and reduced respiratory symptoms. The affordability, taste, and solubility of glycine make it an attractive option for CF patients as a dietary supplement to enhance lung health.

Cysteamine: Fighting bacterial virulence

Cysteamine, an endogenous aminothiol, has exhibited antimicrobial properties that could prove valuable in CF treatment. It prevents biofilm formation by Pseudomonas aeruginosa, reduces the production of virulence factors, and enhances the effectiveness of antibiotics. Research indicates that cysteamine interferes with bacterial pathways involving glycine utilization, reduces hydrogen cyanide production, and mitigates the toxicity of bacterial infections.

These effects make cysteamine a promising candidate for treating CF-related infections, as it reduces bacterial resilience and aids antibiotics in fighting persistent lung infections. Furthermore, it has been shown to inhibit the production of pyocyanin and exopolysaccharides, which are key components in the virulence of Pseudomonas.

Choline: Supporting liver and lung health

Choline is an essential nutrient needed for the synthesis of phosphatidylcholine (PC), which is crucial for liver function, bile formation, and lung health. In CF patients, choline deficiency is common due to impaired bile production and nutrient malabsorption. This deficiency contributes to liver dysfunction and impairs lung function, as choline is necessary for maintaining the balance of surfactant phospholipids in the lungs.

Supplementation with choline has been shown to normalize plasma choline levels in CF patients, enhancing lung function and reducing liver fat accumulation. Correcting choline deficiency could be a key component of comprehensive CF care, helping to maintain pulmonary health and prevent liver complications.

ARINA-1: A Novel Mucoactive Therapy

A new formulation, ARINA-1, combines ascorbic acid, glutathione, and bicarbonate as a nebulized therapy for CF. This combination has shown promise in enhancing mucociliary clearance, a critical process for removing mucus from the respiratory tract. Studies have found that ARINA-1 significantly increases the speed of mucus transport and maintains airway hydration, improving lung function.

The formulation appears to reduce mucus viscosity, making it easier to clear from the airways. Ascorbic acid helps stimulate CFTR-mediated chloride secretion in cells with functional CFTR, though this effect is less pronounced in cells with the F508del mutation. Overall, ARINA-1 represents an innovative approach to managing mucus buildup, potentially improving respiratory outcomes for CF patients.

A promising future for nutraceuticals in cystic fibrosis

Cystic fibrosis is a complex genetic disorder that presents significant challenges for patients and healthcare providers alike. While traditional treatments focus on managing symptoms and preventing complications, the integration of nutraceuticals into CF care offers a promising new approach to improving patient outcomes.

Seaweeds, curcumin, glycine, cysteamine, choline, and ARINA-1 each offer unique benefits that can complement existing CF treatments. From reducing inflammation to supporting immune function and improving nutrient absorption, these natural compounds have the potential to enhance the quality of life for people with CF. As research into these nutraceuticals continues, they may become an integral part of personalized care for cystic fibrosis, helping to bridge the gap between symptom management and addressing underlying disease mechanisms.

While nutraceuticals are not a cure for cystic fibrosis, their ability to target different aspects of the disease makes them valuable tools in the comprehensive management of CF. By incorporating these natural compounds alongside traditional treatments, healthcare providers can offer CF patients a more holistic approach to care, helping them live longer and healthier lives.

Renald Blundell is a biochemist and biotechnologist with a special interest in Natural and Alternative Medicine. He is a professor at the Faculty of Medicine and Surgery, University of Malta.

Manuela Grech is currently a medical student at the University of Malta.

Photo: AI-generated image created by Prof. Blundell